SANGAMO THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $10.36M, a 52.45% decline year-over-year.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $21.79M, a 124.50% increase year-over-year.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $15.11M, a 82.20% decline from fiscal 2022.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $84.87M, a 213.18% increase from fiscal 2021.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $27.10M, a 80.99% decline from fiscal 2020.
- SANGAMO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $142.53M, a 4.56% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-03-31 | $10.36M 10-Q · filed 2026-05-14 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $21.79M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $21.79M derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-03-31 | $21.79M 10-Q · filed 2025-05-12 | $27.19M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $15.11M 10-K · filed 2025-03-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $33.53M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $5.40M 10-Q · filed 2024-08-06 | $75.70M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $9.71M 10-Q · filed 2024-05-09 | $94.57M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $18.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $84.87M 10-K · filed 2024-03-13 |
| 2022-09-30 | $42.17M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $24.27M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $27.10M 10-K · filed 2024-03-13 |
| 2021-09-30 | $2.37M 10-Q · filed 2022-11-03 | $27.10M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $9.08M 10-Q · filed 2022-08-04 | $24.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $15.65M 10-Q · filed 2022-05-05 | $158.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $142.53M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $142.53M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $136.31M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$321.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $136.57M 10-Q · filed 2020-08-05 | |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $215.76M 10-K · filed 2021-02-24 |
| 2018-06-30 | $215.76M 10-Q · filed 2019-08-07 | |
| 2017-12-31 | $81.57M 10-K · filed 2020-02-28 | |
| 2014-12-31 | $93.80M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $69.49M 10-K · filed 2016-02-18 | |
| 2011-12-31 | $50.22M 10-K · filed 2014-02-24 |